<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002768</url>
  </required_header>
  <id_info>
    <org_study_id>CALGB-9620</org_study_id>
    <secondary_id>U10CA031946</secondary_id>
    <secondary_id>CLB-9620</secondary_id>
    <secondary_id>CDR0000064734</secondary_id>
    <nct_id>NCT00002768</nct_id>
  </id_info>
  <brief_title>Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission</brief_title>
  <official_title>AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA IN SECOND REMISSION: A PHASE II STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
      so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation
      may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.

      PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation
      following chemotherapy in treating patients with acute myeloid leukemia in second remission.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the ability of mobilization using cytarabine, etoposide, and
      filgrastim (G-CSF), conditioning using busulfan and etoposide, and autologous peripheral
      blood stem cell transplantation to generate a 2-year disease-free survival rate in at least
      30% of patients with acute myeloid leukemia (AML) in second complete remission. II. Determine
      whether the treatment-related mortality can be limited to less than 20% in patients treated
      with this regimen. III. Determine whether adequate numbers of PBSC can be collected in these
      patients. IV. Determine the engraftment kinetics of primed PBSC obtained from these patients.

      OUTLINE: Mobilization/harvest: Patients receive cytarabine IV over 2 hours every 12 hours and
      etoposide IV continuously on days 1-4. Filgrastim (G-CSF) is administered subcutaneously (SC)
      beginning on day 14 and continuing until peripheral blood stem cells (PBSC) are harvested.
      When blood counts recover, PBSC are harvested and selected for CD34+ cells. Conditioning:
      Beginning at least 4 weeks after hospital discharge for mobilization and harvest and when
      blood counts recover, patients receive oral busulfan every 6 hours on days -7 to -4 and
      etoposide IV over 4 hours on day -3. PBSC are reinfused on day 0. G-CSF is administered SC
      beginning on day 0 and continuing until blood counts recover. Patients with documented CNS
      disease at first relapse receive methotrexate intrathecally at intervals of 1 week or greater
      before and/or after PBSC transplantation for a total of 6 doses. Patients are followed every
      3 months for 2 years and then every 6 months for 3 years.

      PROJECTED ACCRUAL: A total of 26-48 patients will be accrued within 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1996</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">February 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Autologous stem cell transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive consolidation chemotherapy followed by autologous stem cell transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>10 microgram/kg body wt subcutaneously daily beginning on d 14 and con't until peripheral blood collection is completed</description>
    <arm_group_label>Autologous stem cell transplantation</arm_group_label>
    <other_name>G-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>1 mg/kg PO q 6 hrs for 16 doses on days -7 thru -4.</description>
    <arm_group_label>Autologous stem cell transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>2000 mg/ sq meter IV over 2 hours q 12 hrs x 8 doses on days 1-4</description>
    <arm_group_label>Autologous stem cell transplantation</arm_group_label>
    <other_name>Ara-C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>40 mg/kg (total dose) IV cont infusion over 96 hrs on days 1-4 of consolidation therapy and 60 mg/kg IV over 4 hrs on day -3 of transplant</description>
    <arm_group_label>Autologous stem cell transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>For patients with documented CNS disease at first relapse, 12 mg intrathecal for a total of 6 doses given before and/or after transplantation</description>
    <arm_group_label>Autologous stem cell transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Infusion on Day 0</description>
    <arm_group_label>Autologous stem cell transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Diagnosis of acute myeloid leukemia (AML) in second complete
        remission (CR) for 30 days to less than 1 year before study entry Second CR defined by the
        following: Neutrophil count at least 1,000/mm3 Platelet count at least 100,000/mm3 Normal
        bone marrow morphology with no excess blasts (greater than 5%) No myelodysplasia No
        extramedullary or CNS leukemia Initial diagnosis of de novo AML (M0-M7) No prior
        myelodysplasia No myeloproliferative disease No secondary AML Cytogenetics not required No
        cytogenetic evidence of persistent leukemia if cytogenetics performed

        PATIENT CHARACTERISTICS: Age: 15 to 69 Hematopoietic: See Disease Characteristics
        Granulocyte count at least 1,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL AST less than 3
        times normal Alkaline phosphatase less than 3 times normal No cirrhosis or chronic
        hepatitis Biopsy required if chronic liver disease suspected (history of alcohol abuse or
        possible hepatitis) Renal: Creatinine less than 2.0 mg/dL Other: Not pregnant or nursing
        Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior bone marrow/stem cell transplantation
        Chemotherapy: Prior non-ablative chemotherapy at initial diagnosis, during initial
        remission, or as reinduction therapy (to produce current second remission) allowed At least
        4 weeks since hospital discharge after reinduction therapy Endocrine therapy: Not specified
        Radiotherapy: Not specified Surgery: Not specified Other: No prior post-remission therapy
        for second remission
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Linker, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Cancer Center and Cancer Research Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115-0128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marlene &amp; Stewart Greenebaum Cancer Center, University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital and Medical Center</name>
      <address>
        <city>Paterson</city>
        <state>New Jersey</state>
        <zip>07503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Linker CA, Owzar K, Powell B, Hurd D, Damon LE, Archer LE, Larson RA; Cancer and Leukemia Group B. Auto-SCT for AML in second remission: CALGB study 9620. Bone Marrow Transplant. 2009 Sep;44(6):353-9. doi: 10.1038/bmt.2009.36. Epub 2009 Mar 16.</citation>
    <PMID>19289999</PMID>
  </results_reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 21, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2004</study_first_posted>
  <last_update_submitted>June 27, 2016</last_update_submitted>
  <last_update_submitted_qc>June 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute erythroid leukemia (M6)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute promyelocytic leukemia (M3)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

